Suven Life Sciences secures two product patents

One each from Mexico and Singapore

Suven Life Sciences announced the Company secured grant of one (1) product patent from Mexico (325948) and one (1) product patent from Singapore (180674) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of eighteen (18) granted patents from Mexico and twenty (20) granted patents from Singapore. These

 

Powered by Capital Market - Live News